Adaptive Biotechnologies raises 2026 revenue guidance. NASDAQ-listed ADPT projects MRD revenue between $260M and $270M for 2026, reflecting strong confidence in business momentum. The company reported 53% MRD growth in Q1 2026 with an impressive 70% gross margin, demonstrating operational efficiency and pricing power. Management targets positive adjusted EBITDA and free cash flow generation by year-end 2026, a significant milestone for profitability. This guidance raise signals accelerating demand for the company's molecular residual disease testing platform in oncology. Investors should monitor execution risks and competitive dynamics in the precision diagnostics space as the company pursues profitability while maintaining growth momentum.
Post from MarketNews_en
Log in to interact with content.